The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 445)
Therapeutic Pipeline Program, 2017
Addex Pharmaceuticals has developed drug discovery tools that can be used to screen its small molecule compound library for positive allosteric modulators (protein regulators) of TrkB, a neuroprotective receptor. We have screened several independent chemical series of a type of chemical compounds, called TrkB PAMs, which can become optimized (improved) to become potential Parkinso...
Researchers: Robert Lutjens, PhD
Target Advancement Awards, 2017
Parkinson's disease (PD) is characterized by the accumulation of misfolded pathologic alpha-synuclein. This toxic alpha-synuclein moves between neurons and causes progressive neuronal death. Blocking entry of the toxic alpha-synuclein into neurons with an antibody (immune protein) can prevent the progression of neuronal cell death.
Does blocking entry of toxic alpha-sy...
Researchers: Valina L. Dawson, PhD
Research Grant, 2017
Previous research has shown higher levels of the c-Abl protein are activated in the brains of people with Parkinson's disease (PD), and studies have linked c-Abl to pathways associated with the disease. Impeding the activity of this protein could potentially slow or stop the progression of PD, making it an emerging therapeutic target. While much work remains to understand the role ...
Researchers: Tanya Simuni, MD
Therapeutic Pipeline Program, 2016
Mitochondrial dysfunction has a prominent role in the process of Parkinson's disease (PD). Mutations in at least seven genes are known to underlie PD, most of them encode proteins that impact mitochondrial function and clearance, cellular oxidative stress or redox balance. This project aims to repurpose KH176, a molecule currently under development for the treatment of mitochondria...
Researchers: Johannes Albertus Maria Smeitink, MD, PhD
Target Validation Pilot Award, 2016
We hypothesize that the inflammatory protein galectin-3 contributes to PD progression.
We will use pre-clinical models that lack galectin-3 to evaluate inflammation, neuronal cell death and behavior. First, we will test the effect of a toxin called MPTP to produce PD pathology. Next, we will inject a special virus to make brain cells produce the protein alpha-synuclein.